P. Jeffrey

发表

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

S. Robson, G. Drewes, M. Bantscheff, 2011, Nature.

SB-656104-A: a novel 5-HT(7) receptor antagonist with improved in vivo properties.

I. Forbes, G. Riley, P. Jeffrey, 2002, Bioorganic & medicinal chemistry letters.

Stimulation of 5-HT1B receptors causes hypothermia in the guinea pig.

J. Hagan, D. Middlemiss, P. Jeffrey, 1997, European journal of pharmacology.

Orexin-A, an hypothalamic peptide with analgesic properties

A. A. Parsons, E. Irving, A. Hunter, 2001, Pain.

Fused aminotetralins: novel antagonists with high selectivity for the dopamine D3 receptor.

K. Thewlis, G. Riley, G. Stemp, 1998, Bioorganic & medicinal chemistry letters.

Design and synthesis of novel 2,3-dihydro-1H-isoindoles with high affinity and selectivity for the dopamine D3 receptor.

G. Macdonald, K. Thewlis, G. Riley, 2001, Bioorganic & medicinal chemistry letters.

Novel 1,2,3,4-tetrahydroisoquinolines with high affinity and selectivity for the dopamine D3 receptor.

K. Thewlis, G. Riley, G. Stemp, 1999, Bioorganic & medicinal chemistry letters.

Discovery of potent and stable conformationally constrained analogues of the MCH R1 antagonist SB-568849.

G. Hervieu, A. Muir, K. Thewlis, 2006, Bioorganic & medicinal chemistry letters.

The Practice of Medicinal Chemistry

Phillip Jeffrey, P. Jeffrey, 2004 .

1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor.

P. Jeffrey, R. Porter, D. Smart, 2001, Bioorganic & medicinal chemistry letters.

Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase

P. Jeffrey, K. Thewlis, G. Stemp, 2001, Xenobiotica; the fate of foreign compounds in biological systems.

Utility of metabolic stability screening: comparison of in vitro and in vivo clearance

P. Jeffrey, S. Clarke, S E Clarke, 2001, Xenobiotica; the fate of foreign compounds in biological systems.

5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.

A. Brown, D. Middlemiss, S. Bromidge, 1999, Journal of medicinal chemistry.

Characterization of SB‐269970‐A, a selective 5‐HT7 receptor antagonist

J. Hagan, D. Middlemiss, G. W. Price, 2000, British journal of pharmacology.

Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.

J. Hagan, D. Middlemiss, K. Thewlis, 2000, The Journal of pharmacology and experimental therapeutics.

Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A.

P. Jeffrey, T. Ostenfeld, C. Beaumont, 2012, British journal of clinical pharmacology.

SB‐656104‐A, a novel selective 5‐HT7 receptor antagonist, modulates REM sleep in rats

J. Hagan, D. Middlemiss, C. Scott, 2003, British journal of pharmacology.

Toward an improved prediction of human in vivo brain penetration

R N Gunn, J. Passchier, S. Summerfield, 2008, Xenobiotica; the fate of foreign compounds in biological systems.

SAR of biphenyl carboxamide ligands of the human melanin-concentrating hormone receptor 1 (MCH R1): discovery of antagonist SB-568849.

G. Hervieu, Shelagh Wilson, A. Muir, 2006, Bioorganic & medicinal chemistry letters.

Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.

P. Bamborough, R. Prinjha, C. Chung, 2013, Journal of medicinal chemistry.

Anorexia and weight loss in male rats 24h following single dose treatment with orexin-1 receptor antagonist SB-334867

S. Summerfield, J. Blundell, N. Upton, 2005, Behavioural Brain Research.

The effect of SB-236057-A, a selective 5-HT1B receptor inverse agonist, on in vivo extracellular 5-HT levels in the freely-moving guinea-pig

J. Hagan, D. Middlemiss, P. Wyman, 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat.

J. Hagan, D. Middlemiss, K. Thewlis, 2000, Journal of medicinal chemistry.

Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.

David M. Wilson, A. Medhurst, P. Jeffrey, 2013, Bioorganic & medicinal chemistry letters.

Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134).

S. Bromidge, F. King, G. Riley, 2001, Bioorganic & medicinal chemistry letters.

Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist.

J. Hagan, G. Macdonald, D. Middlemiss, 2003, Journal of medicinal chemistry.